Christopher Palmer has been an associate editor at MDedge News since 2017. When he's not tidying grammar, he writes short pieces about breaking FDA announcements and approvals, as well as journal articles. He proudly holds a BA in English and philosophy. Follow him on Twitter @cmacmpalm.
News
Pembrolizumab approved for Merkel cell carcinoma
The FDA granted accelerated approval for the drug based on promising results in nonrandomized, open-label trial.
News
A case of cold burn reported with whole-body cryotherapy
A 71-year-old man presented with a cold burn injury a day after a cryotherapy session for back pain and arthritis.
News
Phase 3 study of novel pemphigus treatment is initiated
Results of a phase 2 study of the BTK inhibitor were positive.
News
Firdapse approved: First treatment for rare autoimmune disorder
Amifampridine (Firdapse) has been approved by the FDA for Lambert-Eaton myasthenic syndrome, which affects the nerves’ connection with muscles.
News
Comorbid depression, anxiety linked to doubled risk of diabetes
“This study provides further support for the notion that depression with comorbid anxiety symptoms might represent a group...
News
Physical activity tied to lower depression risk among older adults
“Meeting WHO recommended [physical activity] levels could be recommended ... to prevent the onset of depression.”
News
FDA approves Sympazan for Lennox-Gastaut syndrome
Patients with Lennox-Gastaut syndrome can have difficulty swallowing pills or large-volume oral suspensions, so this oral film may reduce care...
News
Age, insurance type tied to delay in pediatric febrile UTI treatment
Longer delays in antimicrobial treatment can lead to renal scarring, which also is more likely with older age.
News
FDA approves DNA-based blood type test
This is the first molecular-based test for red blood cell types to report genotypes in its results.
News
FDA approves emicizumab for hemophilia A without inhibitors
Emicizumab-kxwh (Hemlibra) is now approved to treat all age groups with hemophilia A, with or without factor VIII inhibitors.